Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer

Abstract

ObjectiveBiologic disease‐modifying antirheumatic drugs (bDMARDs) are immunosuppressants, and there have been concerns that they might impact tumor immunity in patients with cancer with rheumatoid arthritis (RA). The purpose of this study was to describe the utilization trends of bDMARD in patients with RA after breast cancer (BC) diagnosis.MethodsWe performed a retrospective cohort study of adults with RA and BC (2008 onward) from Optum's de‐identified Clinformatics® Data Mart Database (CDM); the Surveillance, Epidemiology, and End Results Program (SEER) Medicare; and the Texas Cancer Registry (TCR) Medicare databases. We evaluated bDMARD utilization trends during the first three years after BC. We conducted multivariable logistic regression to evaluate the association of utilization with patient characteristics.ResultsA total 1,412 patients were identified in CDM and 1,439 patients in SEER/TCR‐Medicare. During the three months before BC diagnosis, 28.2% (CDM) and 26.9% (SEER/TCR‐Medicare) patients had received bDMARDs. Within the first three years after diagnosis, 24.1% (CDM) and 26.4% (SEER/TCR‐Medicare) were receiving bDMARDs. About 70% of the patients in the two cohorts received glucocorticoids with no significant time trend increases. The largest predictor of bDMARD utilization was prior use before BC (CDM: odds ratio [OR] 27.15, 95% confidence interval [CI] 19.29–38.19; SEER/TCR: OR 18.98, 95% CI 13.72–26.26). Regional and distant BC compared to in situ or localized were also associated with lower bDMARDs utilization in SEER/TCR‐Medicare (OR 0.54, 95% CI 0.36–0.82; OR 0.31, 95% CI 0.13–0.77, respectively).ConclusionThe utilization of tumor necrosis factor inhibitors and other bDMARDs in patients with RA and recent BC has not increased since 2008. Glucocorticoids utilization remained high. The largest predictor of bDMARD utilization was prior use before BC.image